Commodity Channel Index
|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||8.10 - 8.41|
|52 Week Range||6.88 - 24.97|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for STOK
Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 9.72% and 11.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Stoke Therapeutics Inc (NASDAQ: STOK) announced data from a planned interim analysis of the ongoing Phase 1/2a MONARCH and ADMIRAL clinical studies of STK-001 in children and adolescents with Dravet syndrome. Today's results come almost a year after Stoke touted its first-in-human data for STK-001. In addition to positive safety, pharmacokinetic (PK) and cerebrospinal fluid (CSF) exposure data, median reductions in seizure frequency were observed among patients who were treated with multiple dos